CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
CASTLE BIOSCIENCES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$32.16+0.20 (+0.64%)
Close on Oct 19, 2026
- Market cap
- $977.78M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
CASTLE BIOSCIENCES INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dermatologic | $186.92M | $194.51M | $216.37M | $231.56M | $248.09M | $260.62M | $257.00M | $246.50M | $232.59M | $206.79M | $183.38M | $164.74M | 52.3% | -24.7% |
| Non-Dermatologic | $170.36M | $145.41M | $127.86M | $111.98M | $98.18M | $86.46M | $75.07M | $65.38M | $55.00M | $43.93M | $36.41M | $27.27M | 47.7% | +73.5% |
By region
From the segment and revenue-disaggregation notes of Castle Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.